Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06564311 · ClinicalTrials.gov registry record · Phase 2
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
A Phase 2 study of Relapsing Multiple Sclerosis, sponsored by Zenas BioPharma (USA).
- Active
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 20
- Study locations
NCT06564311: Active Phase 2 study of Relapsing Multiple Sclerosis, sponsored by Zenas BioPharma (USA).
NCT06564311 is a Phase 2 study of Relapsing Multiple Sclerosis that is active but no longer recruiting, run by Zenas BioPharma (USA). The registered enrollment target is 93 participants, below the 2,165-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06564311, a Phase 2 study of Relapsing Multiple Sclerosis, is active but no longer recruiting, sponsored by Zenas BioPharma (USA).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
Primary Outcome
Cumulative number of new GdE T1 hyperintense lesions as measured by brain MRI
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Obexelimab
Study Locations (20)
Other
- Neuro-logisch Wien - Vienna
- Rehabilitation & MS Center, Noorderhart Hospital - Overpelt
- AZ Delta-Deltalaan 1 - Roeselare
- Tiantan Hospital, Capital Medical University - Beijing
- The First Affiliation Hospital of Soochow University - Suzhou
- Tianjin Medical University General Hospital - Tianjin
Arizona
- Center for Neurology and Spine - Phoenix
- Perseverance Research Center - Scottsdale
Florida
- Aqualine Clinical Research - Naples
- University of South Florida - Tampa
Wisconsin
- Center for Neurological Disorders - Greenfield
- Medical College of Wisconsin - Milwaukee
Alabama
- North Central Neurology - Cullman
California
- Regina Berkovich MD PhD, Inc - West Hollywood
Massachusetts
- University of Massachusetts Medical School - Worcester
Minnesota
- Infusion Associates Plymouth - Plymouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2024-08-26 |
| Est. Completion | 2026-02 |
| Phase | Phase 2 |
What the registry record for NCT06564311 still lists
NCT06564311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 2,165-participant average among 23 other Relapsing Multiple Sclerosis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Relapsing Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06564311 names 20 study sites across 12 states, led by Other, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06564311 about?
NCT06564311 is a clinical study titled "A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)". This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
What is the current status of trial NCT06564311?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2024-08-26. Estimated completion is 2026-02.
What conditions does trial NCT06564311 study?
This clinical trial studies the following conditions: Relapsing Multiple Sclerosis.
What interventions are being tested in trial NCT06564311?
The interventions under investigation include: Placebo (DRUG), Obexelimab (DRUG).
Who is sponsoring clinical trial NCT06564311?
This trial is sponsored by Zenas BioPharma (USA), which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06564311 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06564311's enrollment target sits among peer trials
93 21st of 23 higher than 3 of 23 other Relapsing Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
COMPLETED · Phase 2
-
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
RECRUITING · Phase 3
-
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 3
-
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
RECRUITING
-
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI